CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 480 enrolled
Drug / intervention
Paliperidone ERdrug
Likely dose
Paliperidone ER 12 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01577186
NCT01577186Phase 4Completed
CompareCT.gov

Symptomatic Remission and Social Function in Patients Treated With Paliperidone ER

Johnson & Johnson Taiwan Ltd·interventional·Posted Apr 13, 2012·Updated Jan 17, 2014

In Brief

A Phase 4 clinical trial evaluating Paliperidone ER for Schizophrenia. Completed, enrolled 480 participants.

Detailed Summary

The purpose of this study is to explore the relationship between achieving symptomatic remission status by means of the 8 items of Positive and Negative Syndrome Scale (PANSS), and personal and social functioning by means of the Personal and Social Performance (PSP) scale in participants treated with flexibly dosed paliperidone ER.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 13, 2012
Enrollment StartJul 1, 2008
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.2 years ago

Interventions

Paliperidone ERdrug

Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.